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Introduction: Down syndrome (DS), a genetic variant of early onset Alzheimer’s dis-
ease (AD), lacks a suitable outcome measure for prevention trials targeting pre-
dementia stages.
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Methods: We used cognitive test data collected in several longitudinal aging studies
internationally from 312 participants with DS without dementia to identify compos-
ites thatwere sensitive to change over time.We then conducted additional analyses to
provide support for the utility of the composites. The compositeswere presented to an
expert panel to determine themost optimal cognitive battery based on predetermined
criteria.
Results: There were common cognitive domains across site composites, which were
sensitive toearly decline. The final composite consistedofmemory, language/executive
functioning, selective attention, orientation, and praxis tests.
Discussion:We have identified a composite that is sensitive to early decline and thus
may have utility as an outcome measure in trials to prevent or delay symptoms of AD
in DS.
KEYWORDS
Alzheimer’s disease, clinical trial outcome, composite measure, Down syndrome, early cognitive
decline
1 BACKGROUND
Down syndrome (DS), most commonly caused by a triplication of chro-
mosome 21, is considered a genetic variant of early onset Alzheimer’s
disease (AD). As a consequence of trisomy 21, individuals with DS
have three copies of the amyloid precursor protein (APP) gene.
This significantly increases the risk of amyloid beta (Aβ) deposition
as plaques and consequently the development of dementia,1 with
over 95% of individuals eventually developing clinical features of
AD.2
The ultra-high risk for AD in association with a high diagnostic cer-
tainty for an underlying Alzheimer pathology in cases with dementia
makes people with DS an important population to consider for ran-
domized controlled trials (RCTs) for interventions that seek to prevent,
delay, or halt the development and progression of dementia.3 Although
there is growing interest in including peoplewithDS in intervention tri-
als, barriers remain for RCTs, including the need for reliable cognitive
outcome measures of progression during the preclinical to prodromal
spectrum stages of dementia.4
Identifying early subtle changes in cognition and diagnosing AD
in DS can be challenging because of the presence of developmen-
tal cognitive impairments associated with lifelong intellectual disabil-
ity (ID) and the variability in baseline cognitive functioning across
individuals.5 However, there are several cognitive tests measuring
memory, verbal fluency, planning, inhibition, attention and visuo-motor
abilities which appear to be appropriate for discriminating between
those with and without dementia and tracking AD-related decline and
progression.6–12 Although these tests show promising results in dis-
tinguishing individuals with and without dementia and may be use-
ful as cognitive endpoints for RCTs, it is currently unclear which tests
show the earliest decline (before dementia can be diagnosed clini-
cally) for use in prevention trials. There is evidence to suggest that
declines inmemory (recall of new information) andattentionoccur first
in DS,9,13 similar to sporadic AD. Other DS studies have found that
impairments in executive functioning and behavioral and psychological
changes precede difficulties in memory.14 Determining which abilities
first show AD-related decline during the transition to the prodromal
phase and identifying the tests most sensitive to change in this period
is vital to determine the most optimal point for an intervention.15 If
a given test is found to be the most sensitive (ie, earliest to change),
then by implication it will likely be a cognitive modality quickest to
change.
To facilitate the development of the first AD prevention trials in
DS, there is a need to refine and adapt current tests of cognition and
identify those which are most sensitive to early AD-related impair-
ments and, therefore, predictive of dementia before the diagnosis can
bemade. Such a test batterywould also be valuable to clinicians by pro-
viding them with predictive measures for tracking AD-related decline.
To this end, we utilized data from existing longitudinal studies associ-
ated with the Horizon 21 DS consortium (H21 consortium),4 as well as
from two DS research cohorts in the United States. The advantages of
this approach includeprovidingamorediverse sampleof cognitivedata
from individuals withDS than is typically possible in single-site studies.
It also capitalizes on the expertise ofmultiple research groups and pro-
vides an opportunity to cross-validate the findings of one cohort with
another in the presence of population, cultural, and language differ-
ences.
Our aim was to use a data-driven approach to identify cognitive
tests or test items that are the most sensitive to detecting early cog-
nitive change in adults with DS. We then sought to use these results
as well as expertise from clinicians and researchers familiar with the
cognitive tools to identify the optimal constellation of tests or test
paradigms to constitute a composite cognitive assessment battery to
use in future RCTs in DS and in clinical settings.
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2 METHODS
2.1 Cohorts
Longitudinal data were used from five observational studies on age-
associated cognitive change in DS. These sites included data from
the Horizon21 study group including the London Down Syndrome
(LonDownS) Consortium in London, UK,12,13 the Dementia in Down
syndrome (DiDs) research cohort in Cambridge, UK,16,17 and the
Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) clinical
cohort in Barcelona, Spain,6,18 in addition to several DS longitudinal
research cohorts from the United States (Neurodegeneration in Aging
Down Syndrome [NiAD] from the Universities of Pittsburgh and
Wisconsin, Madison19), and the Aging in Down syndrome (ADS) study
from University of Kentucky20). Informed consent was obtained from
participants in all cohorts. Because the goal of this project was to
define a cognitive composite endpoint that is sensitive to change in
clinically healthy participants, we restricted our analyses to individuals
whowere 35 years of age or older (as this is the age groupwithinwhich
demonstrable AD pathology is present in DS) and who did not have
a clinical diagnosis of dementia at their baseline visit. Furthermore,
as we were interested in rates of cognitive decline, we included only
participants who had at least two assessments (at baseline and one
or more follow-ups) so that a rate of change could be estimated; all
participants with a minimum of two assessment timepoints (at least 6
months apart, with mean length of follow-up between study cohorts
varying from 1.97 to 3.9 years) were included regardless of other
comorbidities to ensure a representative sample (thosewith severe ID,
significant sensory impairments, or other acute illness that precluded
cognitive testing were excluded from assessments at the site level).
For participants with multiple assessment timepoints, a slope was
estimated across all timepoints. In total, 312 participantsmet inclusion
criteria; the number of participants by site, number of visits, and other
demographic variables are listed in Table 1. Each site administered
a unique test battery spanning several different cognitive domains,
and the specific tests used in each battery are listed in Table S1 in the
supplementarymaterial.
2.2 Statistical analysis
Due to differences in the cognitive tests that were administered as
well as the length and frequency of follow-up, all analyses were con-
ducted separately within each available cohort. We were interested in
the rates of change on each cognitive test and therefore conceptual-
ized “years since baseline visit” as the time variable (hereafter referred
to as “time”). Our modeling strategy then proceeded in several steps.
First, all neuropsychological scores were z-scored to the baseline visit.
Second, a linearmixed-effects model was constructed using the “lme4”
package21 to predict scores on a given cognitive test from the “time”
variable. Random intercepts across participants were included in all
models. Third, we extracted the beta weight of “time” from the model
that indexes the annualized rate of change in z-scores. Fourth, we con-
RESEARCH INCONTEXT
1. Systematic review: A literature search was conducted
using the Scopus database. People with Down syndrome
(DS) are at an ultra-high risk of developing Alzheimer’s
disease (AD) as they age. Although there are currently
tests that are effective at identifying thosewith andwith-
outAD, there is limited research on tests, which are sensi-
tive to prodromal changes for use in preventative clinical
trials of AD in DS.
2. Interpretation: We provide an important component in
expediting the inclusion of people with DS in preven-
tative clinical trials with the development of the H21
AD test battery. It consists of measures of memory, lan-
guage/executive functioning, selective attention, orienta-
tion, and praxis and is a short and comprehensive out-
comemeasure.
3. Future directions: Further examination of the H21 AD
battery is now required to examine its association with
known AD biomarkers.
verted this outcome to a Cohen’s d statistic for ease of comparison
across cohorts.
We repeated steps 2-4 iteratively to evaluate a variety of cogni-
tive composite scores. We first analyzed each cognitive test in isola-
tion; then we averaged two tests together, then three and so on up to
a maximum of six tests in a single composite. This process occurred for
all tests available for a given cohort, resulting in dozens of composite
scores that consisted of the average of between one and six cognitive
tests. For each composite, the Cohen’s d scores were extracted from
the LMEmodel and then rank ordered in terms of absolute magnitude.
Composites with the highest scores were retained for further analy-
sis/discussion. Any test that appeared in three of the five top composite
scores was assumed to tap a cognitive domain (eg, attention, memory,
executive function) that shows large and consistent decline in individu-
als who likely have preclinical AD.We then used these tests to form an
“optimal” composite consisting of the z-scored average of each of the
measures.
2.3 Evaluation of the optimal composite
After selecting the compositewithin each cohortwith the greatest sen-
sitivity to decline, we conducted additional analyses to provide sup-
port for the utility of such a composite in a global clinical trial. First,
we examined individual rates of change on the composite score within
each cohort as a function of critical demographic variables. Specifically,
annualized rates of change for each participant were extracted from a
linear mixed-effects model predicting change in the composite score
over time. These rates of change were then further regressed onto
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TABLE 1 Demographic data from each cohort
Barcelona London Pittsburgh/Wisconsin Cambridge Kentucky
N 128 103 31 19 31
Age (y) 43.8 (6.5) 47.4 (6.6) 42.8 (4.6) 44.1 (5.2) 44.6 (7.0)






















































APOE NA No e4= 75 (73%)
Has e4= 22 (21%)
No e4= 28 (90%)
Has e4= 3 (10%)
No e4= 13 (68%)
Has e4= 4 (21%)
No e4= 11 (35%)
Has e4= 3 (10%)
Number of Visits 3.1 (1.0) 2 (0) 2.3 (0.5) 3.4 (0.8) 3.6 (0.8)
Mean length of
Follow-up (y)
2.5 (1.1) 1.97 (0.06) 3.9 (1.1) 3.7 (1.3) 2.6 (0.7)
Note: Variables are listed as mean (standard deviation) for continuous variables and N (percentage) for categorical variables. Percentages may not sum to
100% due to the presence of missing demographic information.
age, sex, pre-study level of ID at baseline, and length of follow-up to
determine which, if any, entry criteria influence rates of change. Sec-
ond, exploratory power analyses were conducted using the longpower
package22 in R. Specifically, we estimated the number of participants
needed to detect either a 50% slowing or a 30% slowing in the rate of
change for either a 2-year or 3-year clinical trial, as this range repre-
sents a realistic and clinically significant effect size for AD prevention
trials.
2.4 Consensus discussion
Finally, considering the above information, an expert panel of clinicians
and researchers from each site represented in the consortium includ-
ing co-authors (RAB, BB, JBW, BLH, JJ, SVL, SS, FAS, JH, AS) met to
discuss the feasibility of utilizing specific tests in a global clinical trial.
The clinicians and researchers who took part in the consensusmeeting
were all well established and experienced in working with adults with
DS, DS and AD, and clinical trials involving patients with AD. After a
series of group discussions, an optimal cognitive battery was defined
based on the following criteria: (1) it must measure domains that the
statistical analyses indicated show the largest decline over time; (2)
the tests must be amenable to administration in a global trial (ie, not
culturally specific, limit language effects if applied across different lan-
guages); (3) it must be feasible in terms of administration; (4) it must
have face validity as outcome measures of decline related to AD in
RCTs; and (5) it must have low floor and no major ceiling effects in
healthy adults with DS.
3 RESULTS
The average Cohen’s d of the top five cognitive composites in each
cohort ranged from small: 0.28 for Barcelona, to moderate: 0.44
for Kentucky, to large: 1.13 for London, 1.20 for Cambridge, and
1.8 for Pittsburgh/Wisconsin. Cognitive tests, which appeared in at
least three of the top five composites are shown in Table 2, colored
by cognitive domain. Measures of memory, language, attention, and
praxis-type tests were consistently represented across all cohorts.
The means of the “optimal” composite at the baseline and follow-
up visits are plotted in Figure 1. Annualized rates of change (Fig-
ure 2) extracted from linear mixed effects showed cognitive decline
on this composite in all five samples (Pittsburgh/Wisconsin: β=−0.10,
SE = 0.02, P < .001; Kentucky: β= −0.09, SE = 0.05, P = .055; London:
β = −0.11, SE = 0.02, P < .001; Barcelona: β = −0.03, SE = 0.01,
P = .03; Cambridge: β = −0.07, SE = 0.03, P = .02). Regression anal-
yses of the individual rates of change on this composite indicated
that age at baseline (β = −0.001, SE = 0.0003, P < .001) and pre-
study level of ID (β = 0.01, SE = 0.003, P = .003) significantly pre-
dicted rates of change. Sex and length of follow-upwere not significant
predictors.
3.1 Power analysis
As the London cohort had a consistent length of follow-up of ≈2 years
and a good sample size, this cohort was used as the natural history
group to evaluate power. Power analyses were conducted to estimate
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TABLE 2 List of tests that appeared in the top five composites for each cohort
Barcelona London Pittsburgh/Wisconsin Cambridge Kentucky
CAMCOG-DSOrientation
(−0.03)









CAMCOG-DS Praxis (−0.13) Finger-nose pointing
(−0.62)











Cancellation task (−.09) CANTAB SRT (−0.82) CAMCOG-DS Attention
(−0.31)
CEFA Tower of London
(−0.84)




Cohen’sD of the rate of change for each test is listed in parentheses.
CAMCOG,CambridgeCognition Examination; CANTABSRT, Cambridge Executive FunctioningAssessment Simple Reaction Time; CANTABPAL, Cambridge
Executive FunctioningAssessmentPairedAssociate Learning; CEFA,CambridgeExecutive FunctioningAssessment;NEPSY,ADevelopmentalNEuroPSYcho-


























Optimal Composite Means at
 Baseline and Follow−up
F IGURE 1 Optimal composite means from each cohort at the
baseline and follow-up visit
the required sample size to detect a given effect size assuming 80%
power, with trial durations of either 2 or 3 years. Results of the power
analyses are summarized in Table 3. An expected210participants (con-
fidence interval [CI]= 110-545) would be needed in each group (treat-
ment and placebo) to detect a 30% slowing of decline. This number
could be reduced to 150 per group (CI = 79-389) if assessments were
















Annualized change for each cohort
F IGURE 2 Annualized rates of change extracted from the linear
mixed effects
3.2 Consensus discussion
Taking into account the above data, and the predefined parameters for
selecting tests of interest, the following decisions were made from the
tests listed in Table 2: two tests were chosen as the consensus tests for
memory abilities; amodified version of theCuedRecall test (mCRT)6,23
and theCANTABpaired associate learning test (PAL)24; thiswas due to
the importance ofmemory (by accepted diagnostic criteria) in the early
stagesofAD-relateddeclineand thevarietyof different tests thatwere
present in the composites from each cohort. With regard to language
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TABLE 3 Estimated sample sizes (means and confidence intervals) needed to detect a given effect size for a given trial duration and
assessment frequency in the London cohort
50% Effect Size 30% Effect Size
Frequency 2 y 3 y 2 y 3 y
6mo 151 (79-392) 54 (28-141) 419 (220-1090) 150 (79-389)
Annual 189 (99-490) 75 (40-196) 524 (275-1362) 210 (110-545)
Note: estimates are per treatment arm.
abilities, verbal fluency (a simple animal fluency task with 60-second
time limit) was the consensus test. There was a consensus that exist-
ing executive functioning tests may not be reliable in this population
and frequently demonstrate floor effects, as they are too difficult in
DS populations. Because ideational fluency is often regarded as amea-
sure of executive functioning, it was felt that verbal fluency could serve
as a measure of this domain as well. The Cancellation task,25 a test of
selective attention,was selected as themeasure of attentional abilities.
Although theCANTABsimple reaction time test (SRT)would havebeen
ideal given the inclusion of the CANTAB PAL, the SRT task has been
discontinued and is no longer available for use in research studies. The
Purdue Pegboard test26 was chosen as the test of praxis-type abilities
and finally; the orientation subtest of the CAMCOG-DS27 was the con-
sensus test for orientation (see Table 4 for full details).
4 DISCUSSION
This is the first comprehensive analysis of cognitive decline associated
with AD inDS across cohorts regardless of assessment tools used, with
a focus on decline during the earliest transition from the preclinical to
the prodromal stage of AD before a clinical diagnosis of dementia. We
demonstrated a range of effect sizes for different cognitive composites
and between cohorts; the latter was partially explained by baseline dif-
ferences in age and intellectual impairment. Not surprisingly, partici-
pantswhoareolder at entryweremore likely todeclineover the course
of the study. We then identified cognitive domains and specific neu-
ropsychological tests that were consistently represented as important
(ie, sensitive to change) across all cohorts. Our final composite score
included measures of memory, language/executive functioning, selec-
tive attention, orientation, and praxis. Annualized rates of change on
this composite showed cognitive decline in all the cohorts, thus demon-
strating its validity in tracking change during the early stages of AD.
Expert opinion was employed to select tests to use in a final compos-
ite for use as outcomemeasure in clinical trials based on feasibility and
known properties in individuals with DS.
4.1 Patterns of decline associated with
development in AD in DS
This study confirms a pattern of decline that has been emerging in
studies of cognitive AD-related change in DS. For the first time, data
from several data sets have been combined, thus avoiding some of the
issues associated with single research group studies such as admin-
istration and language or cultural effects. Earlier studies highlighted
the importance of decline inmemory,23,28 attention,13,25 and executive
functioning,29 with declines involving memory and attention occurring
before that of declines in measures of executive function in machine-
learningmodels.9
Because AD in DS has, just like in other populations, a strong rela-
tionship with age, it is to be expected that older adults (and cohorts
with higher mean age) would show larger changes on cognitive mea-
sures over time, which was confirmed in our analyses. We also showed
that the degree of premorbid ID influenced effect sizes, which may
be due to those with more severe ID having lower baselines scores,
thus limiting the amount of decline that can be measured over time,
and/or due to greater variability of scores for a given individual, as
it is harder to administer the test reliably for those who are more
intellectually impaired. Although we did not demonstrate any signif-
icant relationships between length of follow-up and effect sizes of
decline onmeasureswhen age, ID level, and sex are taken into account,
this may become apparent in studies with longer follow-up and could
potentially explain differences betweenpreviously reported studies, as
the effect size could be small. Other reasons for differences in effect
sizes between cohorts are the different tests used within the selected
domains; specific tests used within one cohort but not another may
assess subdomains, which are more sensitive to early decline, creating
a discrepancy in the magnitude of the effect reported. Other poten-
tial reasons may be that people who start to show decline have been
dropped out from longitudinal assessments and the threshold at which
people are not offered testing could have differed between sites; or
potential differences in thresholds for clinical dementia diagnosis that
have determined selection of participants included in this analysis.
We excluded participants with an AD diagnosis at baseline, but cross-
country differences between cohorts in their criteria of diagnosing AD
could have an impact on whether the remaining participants are likely
to show change over time, if, for example, those in early prodromal
stage have been already given an AD diagnosis.
4.2 Outcome measure in clinical trials of
treatment to delay cognitive decline in DS individuals
There is renewed interest in the need to target the earlier stages of AD
in the context of a series of failed therapeutics in later stage disease
(including of symptomatic therapies in DS30,31;). DS represents a rel-
atively large population in which such trials are more feasible (due to
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TABLE 4 Details of the recommended test battery
Domain(s)
Test and administration
time Administration & scoring
Primary outcome of
interest




ThemCRT consists of a learning phase and a testing
phase; during the learning phase, 12 items
representing distinct semantic categories are
presented on 3 four-item cards, with each item
accompanied by a unique category cue (Buschke,
1984). Learning is repeated up to amaximum of
three times if necessary. The testing phase consists
of three trials of free and cued immediate recall,
generating twomeasures, a free immediate recall
score (FIRS; spontaneous recall of the list of 12 items
for each trial) and a total immediate score (TIS; FIRS
plus items recalled when the category cuewas
provided). A 20-min delayed recall trial has also been
included, generating two additional scores: free
delayed recall score (FDRS) and a total delayed score
(FDRS plus items recalled after category cuewas
provided). Scoring as per Devenny et al., 2002, and





Computerizedmeasure of visuospatial short-term
memory from the CANTAB battery (CANTAB, 2016);
extended clinical version, with rater rather than
automated prompts; Startin et al., 2015). First trial
score was used. Participants are required to
remember locations of an increasing number of
patterns in progressive stages, hidden behind
“boxes” on the screen. Themain outcome from this
test is the first trial memory score: the number of
pattern locations correctly remembered on the first
trial for each stage attempted. The secondary
outcome is the number of stages completed.






Animal fluency test; number of animals named in 60 s.
Total correct score and adjusted score (0 – 4) are
used.
Total raw score. Adjusted
scores based on the
CAMCOG-DS scoring
can also be used.
Selective attention Cancellation task25 Participants are shown a piece of paper with a clutter of
black andwhite items, and asked to cross-out each
occurrence of a target item, following a practice trial.
Total time to complete the task and total number of






The Purdue Pegboard Test consists of two rows of 25
vertically aligned holes and requires participants to
place asmany pegs as possible in the holes.
Participants do this with their dominant hand, then
with their nondominant hand, and finally with both
hands, within 30 s per condition. The number of pegs
placed in the holes within the time frame is scored.
Dominant hand raw score
Orientation CAMCOG-DS27 Participants are asked several questions regarding
orientation (name, place and time) with possibility of
prompts; potential range of scores between 0 and 12.
Total score
smaller numbers required), and avoiding inclusion of “non-converters
with mild cognitive impairment” as trial participants as often happens
in sporadic AD trials.4 A reliable outcome measure that can be used
to track treatment effects at early stages of decline would help enable
successful clinical trials. However, such outcomemeasures should also
be feasible, easy to administer internationally (independent of lan-
guage or cultural effects), and allow for a scores from participants with
a broad range of baseline cognitive abilities. We identified a brief test
battery, with elements that have been adapted for use in people with
DS, with considerable face validity for use to track AD-related decline.
We then demonstrated observable effect sizes for longitudinal cogni-
tive change across all study groups for the identified brief battery, in
individuals at risk for but not yet presenting with diagnosable demen-
tia due to AD.
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4.3 Further development
The H21 AD test battery will be included in our longitudinal studies of
cognitive decline associatedwithAD inDS.Wewill collect data on test-
retest reliability of this combination of subtests across cohorts, as well
as change in performance over time. Thiswill allow for further analyses
to consider refinement of scoring; for example, to consider the degree
each individual test contributes to an overall score to deliver addi-
tional data to inform the design of future trials. Finally, an important
next stepwould be to relate changes on the new battery to biomarkers
associated with the development of AD in DS, including fluid biomark-
ers such as neurofilament light, plasma, and neuroimagingmeasures of
tau and amyloid.17,32,33 It will also be important to establish the clin-
ical meaningfulness and minimal clinically important difference of the
propose composite by relating change in cognition to important func-
tional or clinical measures such as the rate of progression to demen-
tia or standard measures of activities of daily living using measures
such as the CAMDEX-DS informant interview27,34 and the functional
behavior scales,35 and by using anchor-based and distribution-based
approaches.
4.4 Strengths and limitations
Although we had access to a unique and large sample, some within-
group analyses had limited power. Furthermore, study groups used dif-
ferent assessment batteries and, in some cases, different scoring cri-
teria. Thus our statistical analyses are aimed at the identification of
important cognitive domains rather than the selection of specific neu-
ropsychological tests. The discussion by our consensus group aimed
to supplement the statistical modeling in order to identify the spe-
cific tests that would be most feasible to employ in a global clinical
trial (eg, easy to score, minimal cultural, or language differences). How-
ever, our main objective was to identify robust patterns of decline
regardless of assessment tools used, and therefore diversity in terms
of batteries were beneficial rather than a limitation. Despite the rela-
tively small sample sizes of some data sets, the findings were consis-
tent across the cohorts. Length of follow-up also differed between the
data sets. We minimized the impact that this may have had by limiting
the cases by length of follow-up and used annualized rates of change
on the final composite. Finally, the included cohorts differed slightly in
terms of demographic variables such as age,which explains someof the
observed differences in effect sizes, as age is a strong predictor of cog-
nitive decline in individuals with DS. This was particularly evident in
the London cohort, which included the oldest individuals (and is proba-
blymore representative of the range of intellectual ability amongst the
cohorts) and showed the largest annualized change in performance.
5 CONCLUSIONS
The early markers of cognitive change of AD in DS include prominent
decline in memory, language, attention, and praxis, and appear to be
comparable to decline in other forms of AD, including sporadic AD and
autosomal-dominant AD.We have identified a composite that is sensi-
tive to cognitive change during the early prodromal stage of AD in DS
prior to a diagnosis of dementia that can be used as an outcome mea-
sure in clinical trials of treatment to prevent or delay decline associated
with the disease in DS.
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